Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
cancer susceptibility 16 | 0.780 | 0.308 |
|
disease | 0.200 | None | 1.000 | 11 | 4 | 2007 | 2020 | |||||||||
|
synuclein alpha | 0.427 | 0.885 | 0.88 |
|
disease | 0.700 | None | 0.983 | 11 | 32 | 1997 | 2020 | ||||||||
|
FTO alpha-ketoglutarate dependent dioxygenase | 0.486 | 0.885 | 8.4E-08 |
|
disease | 0.500 | None | 0.954 | 11 | 16 | 2007 | 2020 | ||||||||
|
apolipoprotein B | 0.453 | 0.808 | 1.9E-16 |
|
phenotype | 0.100 | None | 1.000 | 10 | 27 | 2008 | 2013 | ||||||||
|
lipoprotein lipase | 0.474 | 0.808 | 1.3E-09 |
|
phenotype | 0.100 | None | 1.000 | 10 | 44 | 2007 | 2019 | ||||||||
|
HNF1 homeobox A | 0.478 | 0.846 | 0.96 |
|
phenotype | 0.100 | None | 1.000 | 10 | 20 | 2008 | 2019 | ||||||||
|
FTO alpha-ketoglutarate dependent dioxygenase | 0.486 | 0.885 | 8.4E-08 |
|
disease | 0.500 | None | 0.953 | 10 | 58 | 2007 | 2020 | ||||||||
|
high mobility group AT-hook 2 | 0.429 | 0.808 | 0.87 |
|
phenotype | 0.100 | None | 1.000 | 10 | 7 | 2007 | 2013 | ||||||||
|
prostate cancer associated transcript 1 | 0.575 | 0.615 |
|
disease | 0.140 | None | 1.000 | 9 | 5 | 2007 | 2019 | |||||||||
|
cytochrome P450 family 21 subfamily A member 2 | 0.525 | 0.769 | 2.6E-04 |
|
disease | 0.100 | None | 1.000 | 9 | 12 | 2010 | 2018 | ||||||||
|
fibroblast growth factor receptor 2 | 0.380 | 0.808 | 1.00 |
|
disease | 0.700 | None | 0.942 | 9 | 11 | 1991 | 2020 | ||||||||
|
protein tyrosine phosphatase non-receptor type 22 | 0.438 | 0.846 | 3.5E-21 |
|
disease | 0.700 | None | 0.899 | 9 | 4 | 2004 | 2019 | ||||||||
|
3-hydroxy-3-methylglutaryl-CoA reductase | 0.529 | 0.692 | 1.00 |
|
phenotype | 0.100 | None | 1.000 | 9 | 9 | 2008 | 2019 | ||||||||
|
3-hydroxy-3-methylglutaryl-CoA reductase | 0.529 | 0.692 | 1.00 |
|
phenotype | 0.100 | None | 1.000 | 9 | 9 | 2008 | 2013 | ||||||||
|
POU class 5 homeobox 1B | 0.670 | 0.346 | 2.9E-04 |
|
disease | 0.100 | None | 1.000 | 9 | 5 | 2007 | 2019 | ||||||||
|
ATP binding cassette subfamily G member 8 | 0.573 | 0.538 | 2.4E-20 |
|
phenotype | 0.100 | None | 1.000 | 9 | 8 | 2009 | 2019 | ||||||||
|
ATP binding cassette subfamily G member 8 | 0.573 | 0.538 | 2.4E-20 |
|
phenotype | 0.100 | None | 1.000 | 9 | 8 | 2009 | 2013 | ||||||||
|
cancer susceptibility 8 | 0.670 | 0.462 |
|
disease | 0.140 | None | 1.000 | 9 | 5 | 2007 | 2019 | |||||||||
|
cancer susceptibility 8 | 0.670 | 0.462 |
|
disease | 0.100 | None | 1.000 | 9 | 11 | 2007 | 2014 | |||||||||
|
cyclin dependent kinase 6 | 0.471 | 0.731 | 0.98 |
|
phenotype | 0.100 | None | 1.000 | 8 | 4 | 2008 | 2013 | ||||||||
|
cancer susceptibility 19 | 0.769 | 0.423 |
|
disease | 0.100 | None | 1.000 | 8 | 12 | 2007 | 2013 | |||||||||
|
cadherin EGF LAG seven-pass G-type receptor 2 | 0.656 | 0.577 | 1.00 |
|
phenotype | 0.100 | None | 1.000 | 8 | 15 | 2008 | 2019 | ||||||||
|
cadherin EGF LAG seven-pass G-type receptor 2 | 0.656 | 0.577 | 1.00 |
|
phenotype | 0.100 | None | 1.000 | 8 | 15 | 2008 | 2013 | ||||||||
|
polypeptide N-acetylgalactosaminyltransferase 2 | 0.678 | 0.538 | 8.4E-03 |
|
phenotype | 0.100 | None | 1.000 | 8 | 11 | 2008 | 2019 | ||||||||
|
polypeptide N-acetylgalactosaminyltransferase 2 | 0.678 | 0.538 | 8.4E-03 |
|
phenotype | 0.100 | None | 1.000 | 8 | 11 | 2008 | 2013 |